CAR-T Therapy Development Services: Overcoming Poor Trafficking & Physical Barrier

Overcome the key challenges of solid tumor therapy - including poor T-cell trafficking, the immunosuppressive tumor microenvironment (TME), and dense physical barriers - with our CAR-T Therapy Development Services. By integrating advanced CAR construct engineering with oncolytic virotherapy and chemokine signaling modulators, we enable enhanced infiltration, persistence, and cytotoxic activity within solid tumors.

Introduction

The clinical success of CAR-T therapy in liquid cancers has established it as a revolutionary modality. However, translating this success to solid tumors remains limited by the hostile microenvironment, which imposes physical barriers and functional barriers that impair CAR-T trafficking and cause T-cell exhaustion. Modern research, supported by recent literature, mandates a multi-modal strategy combining engineered cell products with TME-modifying agents, such as Oncolytic Virotherapy and targeted Chemokine Modulation, to achieve the required infiltration and sustained cytotoxic activity against solid tumor fortresses.

Fig.1 Strategies to overcome physical barriers in solid tumors for enhanced CAR cell efficacy.¹

Creative Biolabs' CAR-T Development Combat Poor Trafficking & Physical Barrier

Solid tumors, unlike liquid malignancies, are a complex fortress, utilizing a dense stromal scaffold and an actively hostile microenvironment to suppress therapeutic T cells. Creative Biolabs provides integrated solutions focused on dismantling these two core barriers: Trafficking and Immunosuppression. We engineer CAR T/NK cells and their combination partners (such as oncolytic viruses) to ensure maximum cellular penetration and sustained function at the tumor core. The solutions we deliver are:

• TME Remodeling using Oncolytic Viruses (OVs): Design and production of OVs engineered to express pro-inflammatory agents at the tumor site, effectively inducing Immunogenic Cell Death (ICD) and transforming "cold" tumors into "hot," inflamed environments.
• Targeted Trafficking Enhancement: Engineering CAR T cells to ectopically express chemokine receptors that respond to pre-existing, tumor-secreted chemokine gradients, guiding the therapeutic cells directly to the tumor site.
• Stromal Barrier Penetration: Developing CARs that specifically target components of the physical stroma to deplete the physical barrier and facilitate immune cell infiltration.

What We Can Offer

Process

The required starting materials comprise three key elements: target antigen sequences, a lead CAR/TCR construct, and relevant tumor cell lines for testing.

Upon completion, the final deliverables will include a detailed cell characterization report with flow cytometry and RNA-seq data, a ready master virus bank of the engineered oncolytic virus, and a comprehensive preclinical efficacy report detailing in vivo results on T-cell infiltration and survival curves.

Types of Our CAR-T Development Combat Poor Trafficking & Physical Barrier

Advantages

• High-throughput chemokine receptor library screening.
• Customizable tumor matrix barrier-on-chip models.
• Combined drug penetration and imaging assessment platforms.
• Multiscale CAR-T penetration analysis

FAQs

Partner with Us

Creative Biolabs is your expert partner in translating the promise of CAR-T therapy into clinical reality for solid tumors. Our integrated approach - which systematically addresses the critical challenges of poor trafficking, stromal barriers, and T-cell exhaustion through proprietary OV-CAR combination and chemokine-guided engineering - positions your therapeutic candidate for maximum success. We provide the scientific expertise and the robust preclinical data required to confidently advance your program to the clinic. Our veteran biology specialists can help you build a multi-modal strategy to enhance cell therapy against solid tumors. Contact our team to start the conversation.

Reference

1. Olifirenko, Valentina, and Nikolai A Barlev. "A Review of CAR-T Combination Therapies for Treatment of Gynecological Cancers." International Journal of Molecular Sciences vol. 25,12 6595. 15 Jun. 2024. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3390/ijms25126595